138 related articles for article (PubMed ID: 8529965)
1. [Selective type III phosphodiesterase inhibitor as an antithrombotic agent].
Kimura Y
Nihon Yakurigaku Zasshi; 1995 Sep; 106(3):205-16. PubMed ID: 8529965
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
3. OPC-13013, a cyclic nucleotide phosphodiesterase type III, inhibitor, inhibits cell proliferation and transdifferentiation of cultured rat hepatic stellate cells.
Shimizu E; Kobayashi Y; Oki Y; Kawasaki T; Yoshimi T; Nakamura H
Life Sci; 1999; 64(23):2081-8. PubMed ID: 10372650
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.
Souness JE; Hassall GA; Parrott DP
Biochem Pharmacol; 1992 Sep; 44(5):857-66. PubMed ID: 1326964
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor.
Ikeda Y
Thromb Haemost; 1999 Aug; 82(2):435-8. PubMed ID: 10605734
[No Abstract] [Full Text] [Related]
8. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.
Shiraishi Y; Kanmura Y; Itoh T
Br J Pharmacol; 1998 Mar; 123(5):869-78. PubMed ID: 9535015
[TBL] [Abstract][Full Text] [Related]
9. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets.
Simpson AW; Reeves ML; Rink TJ
Biochem Pharmacol; 1988 Jun; 37(12):2315-20. PubMed ID: 2455518
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.
Pan X; Arauz E; Krzanowski JJ; Fitzpatrick DF; Polson JB
Biochem Pharmacol; 1994 Aug; 48(4):827-35. PubMed ID: 7521642
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol Induces PGI2 Production via Activation of the Downstream Epac-1/Rap1 Signaling Cascade to Increase Intracellular Calcium by PLCε and to Activate p44/42 MAPK in Human Aortic Endothelial Cells.
Hashimoto A; Tanaka M; Takeda S; Ito H; Nagano K
PLoS One; 2015; 10(7):e0132835. PubMed ID: 26181635
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.
Kariyazono H; Nakamura K; Shinkawa T; Yamaguchi T; Sakata R; Yamada K
Thromb Res; 2001 Mar; 101(6):445-53. PubMed ID: 11323002
[TBL] [Abstract][Full Text] [Related]
13. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent--II. Inhibition of platelet phosphodiesterase.
Mikashima H; Nakao T; Goto K; Ochi H; Yasuda H; Tsumagari T
Thromb Res; 1984 Sep; 35(5):589-94. PubMed ID: 6091293
[TBL] [Abstract][Full Text] [Related]
14. Anti-platelet therapy: phosphodiesterase inhibitors.
Gresele P; Momi S; Falcinelli E
Br J Clin Pharmacol; 2011 Oct; 72(4):634-46. PubMed ID: 21649691
[TBL] [Abstract][Full Text] [Related]
15. Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors.
Tang KM; Jang EK; Haslam RJ
Eur J Pharmacol; 1994 Jun; 268(1):105-14. PubMed ID: 7925608
[TBL] [Abstract][Full Text] [Related]
16. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor.
Morishita R; Higaki J; Hayashi SI; Yo Y; Aoki M; Nakamura S; Moriguchi A; Matsushita H; Matsumoto K; Nakamura T; Ogihara T
Diabetologia; 1997 Sep; 40(9):1053-61. PubMed ID: 9300242
[TBL] [Abstract][Full Text] [Related]
17. The pharmacology of cilostazol.
Schrör K
Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S14-9. PubMed ID: 12180353
[TBL] [Abstract][Full Text] [Related]
18. Antithrombotic activity of NSP-513, a novel selective phosphodiesterase 3 inhibitor, on femoral arterial thrombosis induced by physical stenosis and electrical current: comparison of antithrombotic and hemodynamic effects.
Hirose H; Mashiko S; Kimura T; Ishida F; Mochizuki N; Nishibe T; Nishikibe M
J Cardiovasc Pharmacol; 2000 Apr; 35(4):586-94. PubMed ID: 10774790
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of the vasodilator-stimulated phosphoprotein (VASP) by the anti-platelet drug, cilostazol, in platelets.
Sudo T; Ito H; Kimura Y
Platelets; 2003 Sep; 14(6):381-90. PubMed ID: 14602552
[TBL] [Abstract][Full Text] [Related]
20. Effects of the cAMP-elevating agents cilostamide, cilostazol and forskolin on the phosphorylation of Akt and GSK-3beta in platelets.
Hayashi H; Sudo T
Thromb Haemost; 2009 Aug; 102(2):327-35. PubMed ID: 19652884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
